Transaction · 0001902368-26-000008

Inrig Jula

Inrig Jula, EVP, HR, D, CMO, reported a transaction classified as exercise at Travere Therapeutics, Inc. involving 32395.000000 shares for an estimated $0.00. Reported holdings after the transaction were 43605.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MEVP, HR, D, CMO
TVTXTravere Therapeutics, Inc.
Trade date
Sep 15, 2026
Filing date
Sep 18, 2026
View on SEC Insider profile
Disclosed value$0Shares × reported price
Shares traded32.3k$0.00 per share
Holdings after43.6kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

TVTX price since this filing

Daily closing prices, with the filing date and available return windows
TVTX · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago -1.0%1w ago +5.3%1d ago +4.8%
Returns since7d -5.3%30d -21.0%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Derivative
Type
exercise
Code M
Identifier
0001902368-26-000008
Employee stock option (right to buy)
Transaction date
Sep 15, 2026
Filed Sep 18, 2026, 01:33 AM · 3d delay
Shares
32,395 sh
$0.00 per share
Estimated value
$0
Computed from shares × price
Holdings after
43,605 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Derivative Transaction Direct Ownership Large Holdings Reduction 10b5-1 Detected
Filing-only score

-20 points

Compact filing score computed from stored Form 4 facts. Version v1.

Low filing signal

This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • derivative_transaction-16 points

    is_derivative = true

    Derivative exercise rows are less discretionary than open-market purchases.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

EVP, Head of R&D & CMO

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

  2. F2

    The weighted average sale price for the transaction reported was $62.0167, and the range of prices were between $61.40 and $62.39. Upon request by the SEC staff, the Issuer, or any security holder of…

  3. F3

    The weighted average sale price for the transaction reported was $62.6242, and the range of prices were between $62.40 and $63.365. Upon request by the SEC staff, the Issuer, or any security holder of…

  4. F4

    The weighted average sale price for the transaction reported was $63.685, and the range of prices were between $63.58 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of t…

  5. F5

    One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of January 31, 2024, and the remaining shares vest in 36 equal monthly installments thereafter…

Original filing · 0001902368-26-000008
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

TVTX